Please wait while the formulary information is being retrieved.
Drug overview for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
Generic name: CEFTAROLINE FOSAMIL ACETATE (sef-TAR-oh-leen)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents
Ceftaroline is a semisynthetic, fifth generation cephalosporin antibiotic.
No enhanced Uses information available for this drug.
Generic name: CEFTAROLINE FOSAMIL ACETATE (sef-TAR-oh-leen)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents
Ceftaroline is a semisynthetic, fifth generation cephalosporin antibiotic.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate) have been approved by the FDA:
Indications:
Escherichia coli pneumonia
Haemophilus influenzae pneumonia
Klebsiella pneumonia
Pneumococcal pneumonia
Pneumonia due to Staphylococcus aureus
Skin and skin structure E. coli infection
Skin and skin structure Klebsiella infection
Skin and skin structure Streptococcus agalactiae infection
Skin and skin structure Streptococcus pyogenes infection
Staphylococcus aureus skin and skin structure infection
Professional Synonyms:
E. coli pneumonia
H. flu pneumonia
H. influenzae pneumonia
Hemophilus influenzae pneumonia
Influenza Bacillus pneumonia
Pfeiffer's Bacillus pneumonia
Pneumonia due to E. coli
Pneumonia due to Escherichia coli
Pneumonia due to Haemophilus influenzae
Pneumonia due to Klebsiella species
Pneumonia due to Klebsiella spp.
Pneumonia due to Staphylococcus pyogenes aureus
Pneumonia due to Streptococcus pneumoniae
Skin & skin soft tissue Streptococcus pyogenes infection
Skin and skin soft tissue Escherichia coli infection
Skin and skin soft tissue infection due to Klebsiella
Skin and skin soft tissue infection due to S. agalactiae
Skin and skin soft tissue S. agalactiae infection
Skin and skin soft tissue Staphylococcus aureus infection
Indications:
Escherichia coli pneumonia
Haemophilus influenzae pneumonia
Klebsiella pneumonia
Pneumococcal pneumonia
Pneumonia due to Staphylococcus aureus
Skin and skin structure E. coli infection
Skin and skin structure Klebsiella infection
Skin and skin structure Streptococcus agalactiae infection
Skin and skin structure Streptococcus pyogenes infection
Staphylococcus aureus skin and skin structure infection
Professional Synonyms:
E. coli pneumonia
H. flu pneumonia
H. influenzae pneumonia
Hemophilus influenzae pneumonia
Influenza Bacillus pneumonia
Pfeiffer's Bacillus pneumonia
Pneumonia due to E. coli
Pneumonia due to Escherichia coli
Pneumonia due to Haemophilus influenzae
Pneumonia due to Klebsiella species
Pneumonia due to Klebsiella spp.
Pneumonia due to Staphylococcus pyogenes aureus
Pneumonia due to Streptococcus pneumoniae
Skin & skin soft tissue Streptococcus pyogenes infection
Skin and skin soft tissue Escherichia coli infection
Skin and skin soft tissue infection due to Klebsiella
Skin and skin soft tissue infection due to S. agalactiae
Skin and skin soft tissue S. agalactiae infection
Skin and skin soft tissue Staphylococcus aureus infection
The following dosing information is available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
Ceftaroline fosamil is commercially available as ceftaroline fosamil monoacetate monohydrate; dosage is expressed in terms of anhydrous ceftaroline fosamil.
Dosage of ceftaroline fosamil must be modified according to the degree of renal impairment in adults with creatinine clearances of 50 mL/minute or less, including those undergoing hemodialysis. (See Table 1.)
Table 1. Ceftaroline Fosamil Dosage for Adults with Renal Impairment
Estimated Creatinine Clearance Recommended Dosage (mL/minute) 31-50 400 mg every 12 hours 15-30 300 mg every 12 hours <15 or receiving hemodialysis 200 mg every 12 hours; on hemodialysis days, give dose after hemodialysis
Dosage adjustments are not necessary if ceftaroline fosamil is used in pediatric patients with creatinine clearances greater than 50 mL/minute per 1.73 m2. Data are insufficient to make dosage recommendations for pediatric patients with creatinine clearances less than 50 mL/minute per 1.73
m2.
Pharmacokinetics of ceftaroline fosamil have not been studied in patients with impaired hepatic function, but hepatic impairment is not expected to have a clinically important effect on systemic clearance of the drug.
Dosage of ceftaroline fosamil should be selected with caution in geriatric patients. Dosage adjustments are not required based on age, but may be required based on age-related changes in renal function. (See Dosage and Administration: Dosage in Renal and Hepatic Impairment.)
Dosage of ceftaroline fosamil must be modified according to the degree of renal impairment in adults with creatinine clearances of 50 mL/minute or less, including those undergoing hemodialysis. (See Table 1.)
Table 1. Ceftaroline Fosamil Dosage for Adults with Renal Impairment
Estimated Creatinine Clearance Recommended Dosage (mL/minute) 31-50 400 mg every 12 hours 15-30 300 mg every 12 hours <15 or receiving hemodialysis 200 mg every 12 hours; on hemodialysis days, give dose after hemodialysis
Dosage adjustments are not necessary if ceftaroline fosamil is used in pediatric patients with creatinine clearances greater than 50 mL/minute per 1.73 m2. Data are insufficient to make dosage recommendations for pediatric patients with creatinine clearances less than 50 mL/minute per 1.73
m2.
Pharmacokinetics of ceftaroline fosamil have not been studied in patients with impaired hepatic function, but hepatic impairment is not expected to have a clinically important effect on systemic clearance of the drug.
Dosage of ceftaroline fosamil should be selected with caution in geriatric patients. Dosage adjustments are not required based on age, but may be required based on age-related changes in renal function. (See Dosage and Administration: Dosage in Renal and Hepatic Impairment.)
Ceftaroline fosamil is administered by IV infusion. Ceftaroline fosamil solutions should not be admixed with or added to solutions containing other drugs.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CEFTAROLINE FOSAMIL 400 MG VL | Maintenance | Adults infuse 600 mg over 5-60 minute(s) by intravenous route every 12 hours |
| CEFTAROLINE FOSAMIL 600 MG VL | Maintenance | Adults infuse 600 mg over 5-60 minute(s) by intravenous route every 12 hours |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CEFTAROLINE FOSAMIL 400 MG VL | Maintenance | Adults infuse 600 mg over 5-60 minute(s) by intravenous route every 12 hours |
| CEFTAROLINE FOSAMIL 600 MG VL | Maintenance | Adults infuse 600 mg over 5-60 minute(s) by intravenous route every 12 hours |
The following drug interaction information is available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
There are 3 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
| Fecal Microbiota/Antibiotics SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Fecal microbiota is a suspension of live bacteria, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota. Antibacterial treatment should be completed for 24 to 72 hours before initiating treatment with fecal microbiota. Do not use antibiotics for up to 8 weeks after fecal microbiota.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota. |
REBYOTA |
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Slt Anticoagulants (Vit K antagonists)/Slt Cephalosporins SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism is unknown, but may involve a combination of cephalosporin induced platelet inhibition and alteration of gut flora. CLINICAL EFFECTS: Concurrent use of some cephalosporins may increase the hypoprothrombinemic effect of the anticoagulant with possible bleeding. PREDISPOSING FACTORS: High doses, hepatic and/or renal impairment, and poor nutrition may increase the risk of bleeding. The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: Monitor prothrombin activity and adjust the anticoagulant dosage accordingly. Consider using an alternative antibiotic. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. DISCUSSION: Although the majority of cephalosporins that have been documented to interact with anticoagulants have a NMTT side chain, there are reports of interactions with cefazolin, cefoxitin, ceftaroline, and ceftriaxone as well. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. A large systematic review was performed on 72 warfarin drug-drug interactions studies that reported on bleeding, thromboembolic events, or death. Most studies were retrospective cohorts. A meta-analysis of 11 of those studies found a higher rate of clinically significant bleeding in patients on warfarin and antimicrobials (OR=1.63; 95% CI 1.45-1.83). Increased bleeding risk was also seen in subgroup analyses with cephalosporins (OR=1.50; 95% CI 1.21-1.86). |
ANISINDIONE, DICUMAROL, PHENINDIONE, WARFARIN SODIUM |
The following contraindication information is available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Clostridioides difficile infection |
| Hemolytic anemia |
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Lower seizure threshold |
| Myoclonus |
| Seizure disorder |
The following adverse reaction information is available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 16 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abnormal hepatic function tests Hypokalemia Increased alanine transaminase Increased aspartate transaminase |
| Rare/Very Rare |
|---|
|
Agranulocytosis Anaphylaxis Bradycardia Clostridioides difficile infection Encephalopathy Eosinophilic pneumonia Hemolytic anemia Hepatitis Hyperkalemia Renal failure Seizure disorder Thrombocytopenic disorder |
There are 18 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Diarrhea Nausea Skin rash |
Constipation Fever Headache disorder Phlebitis after infusion Pruritus of skin Vomiting |
| Rare/Very Rare |
|---|
|
Acute abdominal pain Anemia Dizziness Eosinophilia Hyperglycemia Myoclonus Neutropenic disorder Palpitations Urticaria |
The following precautions are available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Adequate data are not available regarding use of ceftaroline fosamil in pregnant women. Animal studies in rats using ceftaroline fosamil dosages up to 4 times the maximum recommended human dosage (MRHD) or in rabbits using dosages up to approximately equal to the MRHD have not revealed evidence of fetal harm.
It is not known whether ceftaroline is distributed into human milk; possible effects of the drug on a breast-fed infant or on milk production are unknown. Benefits of breast-feeding and the importance of ceftaroline fosamil to the woman should be considered along with the potential adverse effects on the breast-fed infant from the drug or from the underlying maternal condition.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate)'s list of indications:
| Escherichia coli pneumonia | |
| J15.5 | Pneumonia due to escherichia coli |
| Haemophilus influenzae pneumonia | |
| J14 | Pneumonia due to hemophilus influenzae |
| Klebsiella pneumonia | |
| J15.0 | Pneumonia due to klebsiella pneumoniae |
| Pneumococcal pneumonia | |
| J13 | Pneumonia due to streptococcus pneumoniae |
| Pneumonia due to staphylococcus aureus | |
| J15.21 | Pneumonia due to staphylococcus aureus |
| J15.211 | Pneumonia due to methicillin susceptible staphylococcus aureus |
| J15.212 | Pneumonia due to methicillin resistant staphylococcus aureus |
| Skin and skin structure e. coli infection | |
| B96.2 | Escherichia coli [e. coli ] as the cause of diseases classified elsewhere |
| B96.20 | Unspecified escherichia coli [e. coli] as the cause of diseases classified elsewhere |
| B96.29 | Other escherichia coli [e. coli] as the cause of diseases classified elsewhere |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Skin and skin structure klebsiella infection | |
| B96.1 | Klebsiella pneumoniae [k. pneumoniae] as the cause of diseases classified elsewhere |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Skin and skin structure strep agalactiae infection | |
| B95.1 | Streptococcus, group b, as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Skin and skin structure strep. pyogenes infection | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Staphylococcus aureus skin and skin structure infection | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.02 | Furuncle of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.12 | Furuncle of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.217 | Cutaneous abscess of flank |
| L02.22 | Furuncle of trunk |
| L02.221 | Furuncle of abdominal wall |
| L02.222 | Furuncle of back [any part, except buttock and flank] |
| L02.223 | Furuncle of chest wall |
| L02.224 | Furuncle of groin |
| L02.225 | Furuncle of perineum |
| L02.226 | Furuncle of umbilicus |
| L02.227 | Furuncle of flank |
| L02.229 | Furuncle of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.32 | Furuncle of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.42 | Furuncle of limb |
| L02.421 | Furuncle of right axilla |
| L02.422 | Furuncle of left axilla |
| L02.423 | Furuncle of right upper limb |
| L02.424 | Furuncle of left upper limb |
| L02.425 | Furuncle of right lower limb |
| L02.426 | Furuncle of left lower limb |
| L02.429 | Furuncle of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.52 | Furuncle hand |
| L02.521 | Furuncle right hand |
| L02.522 | Furuncle left hand |
| L02.529 | Furuncle unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.62 | Furuncle of foot |
| L02.621 | Furuncle of right foot |
| L02.622 | Furuncle of left foot |
| L02.629 | Furuncle of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.82 | Furuncle of other sites |
| L02.821 | Furuncle of head [any part, except face] |
| L02.828 | Furuncle of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.92 | Furuncle, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.31A | Cellulitis of flank |
| L03.32A | Acute lymphangitis of flank |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
Formulary Reference Tool